# Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients

> **NCT01402284** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 45 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Carfilzomib
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone
- **DRUG:** Lenalidomide
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT01402284
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07-21
- **Primary completion:** 2016-07-10
- **Final completion:** 2020-09-24
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2021-03-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01402284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01402284, "Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01402284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*